Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - PowerPoint PPT Presentation

Loading...

PPT – Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 PowerPoint presentation | free to download - id: 81bfd3-NzZiN



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021

Description:

Download Sample Brochure of report @ A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Breast Cancer Therapeutics in Asia-Pacific Markets and future opportunities are provided in the report. – PowerPoint PPT presentation

Number of Views:8

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Breast Cancer Therapeutics in Asia-Pacific Markets to 2021


1
Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Increasing
Uptake of Premium Priced Biologics and Rising
Prevalence
Published on 04 February, 2016 Number of
pages 171 Single User Price 4995
2
Breast cancer, a malignant neoplasm, is the
second-most common cancer and the most common
cancer in women worldwide, accounting for 16 of
all female cancers, making the disease
exceedingly prevalent. In the past, breast cancer
occurred less in women in Asia than women in
Western countries. However, recent studies show
that breast cancer is being diagnosed more
frequently in women living in Asia, especially
among younger women. There have been
wide-reaching changes in the breast cancer market
over the past four decades, particularly in
relation to the usage of targeted therapies,
which has increased significantly. The marketed
products landscape comprises a wide range of
treatment options, including hormonal therapies,
chemotherapies, combination therapies and
targeted therapies. The market is set to be
driven by a number of new approvals for drugs and
an increased uptake of premium targeted
therapies. Nevertheless, significant unmet need
remains for products that can improve overall
survival rate, time to disease progression, and
overall response.
3
  • The current breast cancer market contains novel
    products, including Perjeta, a targeted therapy
    Kadcyla, a human antibody-drug conjugate and
    Halaven, a novel chemotherapeutic agent.
  • What are the competitive advantages of the
    existing novel drugs?
  • Are these targeted therapies used to the same
    magnitude in all the countries assessed?
  • What are the factors contributing to the uptake
    of these drugs in each country?
  • With over 700 active pipeline molecules, most of
    the investigational drug candidates are being
    evaluated for the first-line or second-line
    treatment of advanced-stage breast cancer,
    featuring new combination therapies, targeted
    therapies, and promising immunotherapies, as well
    as chemotherapy drug candidates.
  • Which classes of novel drugs are most prominent
    within the pipeline?
  • Is there strong potential for the pipeline to
    address unmet needs within the breast cancer
    market?
  • Which Asia-Pacific countries should expect a late
    launch and a lower uptake of the late-stage
    pipeline drugs?
  • Analysis of clinical trials since 2006 identified
    that the failure rates of breast cancer molecules
    were highest in Phase II (41), with the overall
    attrition rate for breast cancer in development
    being 61.
  • How do failure rates vary by product stage of
    development, molecule type, and mechanism of
    action?
  • How do other factors, such as average trial
    duration and trial size, influence the costs and
    risks associated with product development?

Click Here To Check Complete Report
4
Over the 2014-2021 period, the value of the
Asia-Pacific markets for breast cancer
therapeutics is expected to increase at a
compound annual growth rate of 8.5, from 1.9
billion to over 3.4 billion. Which markets
make the most significant contribution to the
current market size? What are the epidemiology
trends in these markets? Will new market
entrants lead to substantial changes in annual
therapy costs? How will different treatment
usage patterns impact growth in the Asia-Pacific
markets? What are the various trends observed
in the market over the forecast period in each of
the countries? Rising breast cancer prevalence
and increasing use of premium targeted therapies
along with new product approvals will lead to
significant market growth over the forecast
period, despite generic sales erosion resulting
from patent expirations. Will patent
expirations or emerging pipeline molecules
threaten the commercial success of existing
drugs? Various drivers and barriers would
influence the market over the forecast
period. What are the barriers that limit the
uptake of premium-priced therapeutics in the
accessed countries? Which factors are most
likely to drive the market in these countries?
Download Sample Brochure
5
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors?  You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
Make an Inquiry Before Buying
6
Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Increasing
Uptake of Premium Priced Biologics and Rising
Prevalence
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Increasing
Uptake of Premium Priced Biologics and Rising
Prevalenceand future opportunities are provided
in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy ofBreast Cancer
Therapeutics in Asia-Pacific Markets to 2021
About PowerShow.com